NCT05235607

Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sichuan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This single center, single arm and prospective study aimed to establish gene mutation database and select the neoantigens in patients with advanced malignant melanoma, bladder cancer and colorectal cancer. Then, we intended to explore the safety and efficacy of individual tumor antigen-sensitized DC vaccine and their sensitized T cells in these solid cancers.

Conditions

• Carcinoma
• Melanoma
• Bladder Cancer
• Colorectal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration	subcutaneous administration

Timeline

• Start date: 2022-03-01
• Primary completion: 2023-06-01
• Completion: 2023-12-02
• First posted: 2022-02-11
• Last updated: 2022-02-11

Locations

1 site across 1 country: China